Biogen(US:BIIB) Zacks Investment Researchยท2024-02-28 23:46Company Performance - Biogen Inc. (BIIB) ended the latest trading session at $221.74, reflecting a -0.98% change from the previous close, which is less than the S&P 500's daily loss of 0.17% [1] - Over the past month, Biogen's shares have decreased by 9.37%, while the Medical sector gained 5.93% and the S&P 500 gained 3.98% [1] - The upcoming earnings report is expected to show an EPS of $3.47, a 2.06% increase from the prior-year quarter, with revenue estimated at $2.32 billion, indicating a 5.67% decrease year-over-year [1] Fiscal Year Estimates - For the entire fiscal year, the Zacks Consensus Estimates predict earnings of $15.48 per share and revenue of $9.45 billion, reflecting changes of +5.16% and -3.91% from the previous year, respectively [2] - Recent modifications to analyst estimates for Biogen indicate evolving short-term business trends, with positive revisions suggesting a favorable outlook on the company's health and profitability [2] Valuation Metrics - Biogen currently has a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having decreased by 1.51% in the past month [3] - The company is trading at a Forward P/E ratio of 14.46, which is a discount compared to the industry's average Forward P/E of 22.45 [3] - Biogen's PEG ratio stands at 1.87, compared to the Medical - Biomedical and Genetics industry's average PEG ratio of 1.51 [3] Industry Overview - The Medical - Biomedical and Genetics industry ranks in the top 34% of all industries, with a current Zacks Industry Rank of 85 [4] - The strength of individual industry groups is measured by the Zacks Industry Rank, which is based on the average Zacks Rank of individual stocks within these groups [4]